Amid safety concerns, ADC Therapeutics plots 17% staff cuts to push resources behind Zynlonta
24th June 2026 Uncategorised 0In the wake of a recent safety scare in a confirmatory trial of its antibody-drug conjugate Zynlonta, ADC Therapeutics is tightening its belt in an effort to get the most out of its cancer med. More: Amid safety concerns, ADC
read more